RecruitingNot ApplicableNCT07026110

Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer

Sponsor

RenJi Hospital

Enrollment

100 participants

Start Date

Dec 23, 2024

Study Type

INTERVENTIONAL

Conditions

Lung Cancer Lung Neoplasms Lung Cancer Metastatic Lung Diseases Lung Inflammation

Summary

This study aims to explore the efficacy of Trop2, EpCAM-specific PET/CT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel target-specific PET/CT examinations and conventional 18F-FDG PET/CT in the diagnosis and differential diagnosis of solid lung nodules.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether a specialized type of PET/CT scan can more accurately distinguish between cancerous and non-cancerous lung nodules, helping doctors avoid unnecessary surgery in people suspected of having non-small cell lung cancer (NSCLC). **You may be eligible if...** - You are between 18 and 80 years old - Imaging has found a solid lung nodule 8mm or larger that is suspicious for lung cancer - Your doctor has recommended a PET/CT scan and surgery or biopsy according to current guidelines - You or your family has agreed to participate and signed a consent form **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have had prior surgery or trauma significantly affecting how the scan distributes in your body - You have a severe systemic disease or a known allergy to study materials - You are unable to cooperate with the PET/CT procedure - You have had significant radiation exposure from another clinical study in the past year Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[68Ga]Ga-NOTA-T4

Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.

DRUG[68Ga]Ga-NOTA-RT4

Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RT4 injection.

DRUG[18F]F-RESCA-T4

Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.

DRUG[18F]F-RESCA-RT4

Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RT4 injection.

DRUG[18F]F-RESCA-EPCD6

Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-EPCD6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-EPCD6 injection.

DRUG[68Ga]Ga-NOTA-EPCD6

Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-EPCD6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-EPCD6 injection.